In the near term, we have the opportunity to explore the potential sale of the division (Diagnostics) for cash (and maintain a royalty), IPO the entity, license the technologies to a third party, or evaluate other strategic options that may present themselves now that we have created critical mass.

It would appear that in the next month or two there should be some better traction on where we are headed in regards to the DX division